| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003852953 |
| P356 | DOI | 10.1186/1471-2407-12-555 |
| P932 | PMC publication ID | 3517741 |
| P698 | PubMed publication ID | 23176370 |
| P5875 | ResearchGate publication ID | 233766538 |
| P2093 | author name string | Arlene Chan | |
| Belinda Brown | |||
| David Ingram | |||
| Adrienne Morey | |||
| Diana Hastrich | |||
| Peter Willsher | |||
| P2860 | cites work | Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. | Q46167485 |
| Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy | Q46542698 | ||
| HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. | Q54614183 | ||
| Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites | Q59567861 | ||
| HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process | Q74054441 | ||
| Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer | Q74299719 | ||
| Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma | Q81565196 | ||
| Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients | Q82907142 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens | Q33407727 | ||
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors | Q35808400 | ||
| HER2 gene status in primary breast cancers and matched distant metastases | Q35906294 | ||
| Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status | Q36458793 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes | Q37457262 | ||
| Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer | Q37468681 | ||
| Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. | Q43254569 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast carcinoma | Q18555947 |
| P304 | page(s) | 555 | |
| P577 | publication date | 2012-11-24 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease | |
| P478 | volume | 12 |
| Q49796316 | Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. |
| Q41932946 | Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation |
| Q34834419 | Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis |
| Q41812451 | Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer |
| Q26780318 | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach |
| Q38810954 | Molecular Concordance Between Primary Breast Cancer and Matched Metastases. |
| Q89661763 | Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99 |
| Q50120368 | Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis |
| Q40409180 | St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. |
Search more.